HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

A SPECTRUM OF PHARMACOLOGICAL EFFECTS OF GLYCINE

Download full text PDF
Issue: 
12
Year: 
2015

T. Potupchik (1), Candidate of Medical Sciences; O. Veselova (1), Candidate of Medical Sciences; L. Evert (2), MD; Ya. Nartsissov (3), Candidate of Physical and Mathematical Sciences; I. Gatskikh (1), I. Bryukhanova (1); M. Anisimova (1) 1 -Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University 2 -Research Institute for Medical Problems of the North, Krasnoyarsk 3 -Research Institute of Cytochemistry and Molecular Pharmacology, National Research Nuclear University, Moscow Engineering Physics Institute, Moscow

The paper gives a broad spectrum of pharmacological effects of Glycine and the results of clinical trials evaluating its efficacy in therapeutic and pediatric practice in the contexts of the results of some fundamental studies.

Keywords: 
amino acids
glycine
neurotransmitters



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Abduvaliev A.A., Zohidov Zh.M., Nishantaev M.K. i dr. Vlijanie glitsina na aktivnost' katalazy v dinamike eksperimental'nogo infarkta miokarda // Uspehi sovremennogo estestvoznanija. – 2013; 9: 11.
  2. Borozdun S.V., Panicheva E.S., Bobrova E.I. i dr. Sovremennye napravlenija v issledovanii etiopatogeneza idiopaticheskogo skolioza u detej // Jakutskij meditsinskij zhurnal. – 2011; 35 (3): 10–4.
  3. Burchinskij S.G. Opasnosti i riski nootropnoj farmakoterapii: mif ili real'nost'? // Rats. farmakoter. – 2007; 1: 62–6.
  4. Gatskih I.V., Veselova O.F., Brikman I.N. i dr. Kognitivnye narushenija pri saharnom diabete 2 tipa // Sovremennye problemy nauki i obrazovanija. – 2015; 4.
  5. Gatskih I.V., Veselova O.F., Brikman I.N. i dr. Rol' mozgovogo nejrotroficheskogo faktora (BDNF) v patogeneze nevrologicheskih rasstrojstv u patsientov s saharnym diabetom // Sovremennye problemy nauki i obrazovanija. – 2015; 4.
  6. Goncharova O.V., Vahrameeva S.N. Metabolitnaja terapija: perspektivy primenenija. Materialy Nauchno-prakticheskoj konferentsii pediatrov Rossii «Farmakoterapija i farmakogenetika v pediatrii». M., 26–28 sentjabrja 2000 g.; 41.
  7. Gorina A.S., Kolesnichenko L.S. Aminokisloty syvorotki krovi i mochi u detej s sindromom Aspergera // Sib. med. zhurn. – 2011; 7: 69–73.
  8. Grigorova O.V., Romasenko L.V., Fajzulloev A.Z. i dr. Primenenie Glitsina v lechenii patsientov, stradajuschih rasstrojstvom adaptatsii // Prakticheskaja meditsina. – 2012; 57 (2): 178–82.
  9. Zajtseva O.I., Tereschenko V.P., Prahin E.I. i dr. Osobennosti formirovanija vegetativnogo gomeostaza u detej shkol'nogo vozrasta v razlichnyhregionah Sibiri // Uspehi sovremennogo estestvoznanija. – 2005; 4: 13–6.
  10. Zubatkina O.V., Malahova M.Ja. Izmenenija srednemolekuljarnogo pula veschestv pri prieme glitsina // Efferentnaja terapija. – 2000; 6 (1): 63–5.
  11. Popov S.B., Sljusarenko I.T. Otchet o provedenii ogranichennyh klinicheskih ispytanij preparata Glitsised®-KMP (proizvodstvo OAO«Kievmedpreparat»). Ukrainskaja farmatsevticheskaja akademija, klinicheskajabaza Farmakologicheskogo komiteta MZO Ukrainy. Har'kov, 1998.
  12. Selin A.A., Lobysheva N.V., Vorontsova O.N. i dr. Mehanizm dejstvija glitsina kak protektora narushenija energetiki tkanej mozga v uslovijah gipoksii // Bjul. eksperim. biologii i meditsiny. – 2012; 153 (1): 52–5.
  13. Ton'shin A.L., Lobysheva N.I., Jaguzhinskij L.S. i dr. Vlijanie tormoznogo nejromediatora glitsina na medlennye destruktivnye protsessy v srezah kory bol'shih polusharij golovnogo mozga pri anoksii // Biohimija. –2007; 72 (5): 631–41.
  14. Shejbak L.N. Osobennosti obespechenija i potrebnost' v aminokislotah v periode novorozhdennosti // Vestnik VGMU. – 2015; 14 (2): 23–30.
  15. Evert L.S., Borozdun S.V., Bobrova E.I. i dr. Diagnostika displazii soedinitel'noj tkani s ispol'zovaniem biomarkerov // Journal of Siberian Federal University. Chemistry. – 2009; 4: (2): 385–90.
  16. Juldashov S.I., Juldashev N.M., Alimhodzhaeva N.T. i dr. Aktivnost' superoksiddismutazy v dinamike eksperimental'nogo infarkta miokarda i na fone lechenija glitsinom // Uspehi sovremennogo estestvoznanija. – 2013; 9: 75–6.
  17. Jakovleva E.V. Vlijanie glitsina na psihoemotsional'nye i vegetativnye narushenija u bol'nyh revmatoidnym artritom // Retsept. – 2006; 2: 103–9.
  18. Abramov A., Scorziello A., Duchen M. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation // J. Neurosci. – 2007; 27 (5): 1129–38.
  19. Brosnan J., Brosnan M. Creatine metabolism and the urea // Mol. Genet Metab. – 2010; 100 (1): 49–52.
  20. Pereira S. et al. Insulin resistance of protein metabolism in type 2 diabetes // Diabetes. – 2008; 57 (1): 56–63.
  21. Wang J. et al. Gene expression is altered in piglet small intestine by weaning and dietary glutamine supplementation // J. Nutr. – 2008; 138 (6): 1025–32.
  22. Cohen B. GABA-transaminase, the liver and infantile autism // Med. Hypotheses. – 2001; 57 (6): 673–4.
  23. Connors S., Crowell D. Secretin and autism: the role of cysteine // J. Am. Acad. Child Adolesc. Psychiatry. – 1999; 38 (7): 795–6.
  24. Evans C., Dunstan R., Rothkirch T. et al. Altered amino acid excretion in children with autism. // Nutr. Neurosci. – 2008; 11 (1): 9–17.
  25. James S., Melnyk S., Jernigan S. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism // Am. J. Med. Genet. B Neuropsychiatr. Genet. – 2006; 5 (8): 947–56.
  26. Kałuzna-Czaplinska J., Michalska M., Rynkowski J. Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry // Med. Sci. Monit. – 2010; 16 (10): 488–92.
  27. Muller W. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain // Biochem. Pharmacol. – 1997; 53: 135–40.
  28. Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development // Pharm. Res. – 2007; 24 (9) 1745–58.
  29. Nishimura Y., Lemasters J. Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia // Cell Death Differ. – 2001; 8: 850–8.
  30. Podoprigora G., Nartsissov Y., Aleksandrov P. Effect of glycine on microcirculation in pial vessels of rat brain // Bull. Exp. Biol. Med. – 2005; 139 (6): 675–7.
  31. Raevskii K., Romanova G., Kudrin V. et al. Balans nejromediatornyh aminokislot i narusheniya integrativnoj deyatel’nosti mozga, vyzvannye lokal’noj ishemiej frontal’noj kory u krys: effekty piracetama i glicina // Bull. Exp. Biol.
  32. Med. – 1997; 123 (4): 370–3.
  33. Wahlgren N. A review of earler clinical studies on neuroprotective agents and current approaches. In: Neuroprotective Agents and Cerebral Ischaemia. Eds. A. Green, A. Cross / Acad. Press Limited, 1997; 337–63.
  34. Wu G. Functional Amino Acids in Growth, Reproduction, and Health // Adv. Nutr. – 2010; 1 (1): 31–7.
  35. Zhang S., Shi J., Tang Z. et al. Protective effects of glycine pretreatment on brain-death donor liver // Hepatobiliary Pancreat. Dis. Int. – 2005; 4 (1): 37–40.
  36. Zhao P., Qian H., Xia Y. GABA and glycine are protective to mature but toxic to immature rat cortical neurons under hypoxia // Eur. J. Neurosci. – 2005; 22 (2): 289–300.
  37. Zhong Z., Wheeler M., Li X. et al. L-Glycine: a novel antiinflamatory, immunomodulatory, and cytoprotective agent // Curr. Opin. Clin. Nutr. Metab. Care. – 2003; 6 (2): 229–40.
  38. Wu G. Amino acids: metabolism, functions, and nutrition // Amino Acids. – 2009; 37 (1): 1–17.